Search Results - kimi+yuk-ling+kong

1 Results

Sort By:

I have demonstrated that BRCA1-mutant triple-negative breast cancer (TNBC) cells are highly sensitive to cyclosporine (CsA) and non-immunosuppressive CsA-derivatives (NIM811 or Alisporivir). To determine whether CsA would also be effective in treating BRCA1-mutant TNBC cells in vivo, I set up a pilot study using a preclinical xenograft model to investigate...

Published: 10/5/2021 | Inventor(s): Kimi Yuk-Ling Kong

Keywords(s):

Category(s): Clinical Specialty > Oncology, Clinical Specialty > Women's Health, Clinical Specialty > Endocrinology, Life Sciences Research Tools > Drug Screening, Therapeutics > Small Molecule